CABALETTA BIO, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
CABALETTA BIO, INC. (CABA) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of -$25.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2026-08-13
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2026-03-31 was -$25.00K.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-09-30 was $22.00K, a 26.67% decline year-over-year.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2025-06-30 was $1.00K, a 88.89% decline year-over-year.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-09-30 was $30.00K.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2025 was $25.00K.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2024 was -$39.00K, a 145.35% decline from fiscal 2023.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $86.00K.
- CABALETTA BIO, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was -$47.00K.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month as first filed | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|---|
| 2026-03-31 | -$25.00K 10-Q · filed 2026-08-13 | -$25.00 10-Q · filed 2026-05-14 | |||
| 2025-12-31 | $25.00K 10-K · filed 2026-03-23 | ||||
| 2025-09-30 | $22.00K 10-Q · filed 2025-11-10 | $23.00K derived: sum of 2 quarters · filed 2026-08-13 | |||
| 2025-06-30 | $1.00K 10-Q · filed 2026-08-13 | ||||
| 2024-12-31 | -$39.00K 10-K · filed 2026-03-23 | ||||
| 2024-09-30 | $30.00K 10-Q · filed 2025-11-10 | $39.00K derived: sum of 2 quarters · filed 2025-11-10 | -$38.00K derived: sum of 3 quarters · filed 2025-11-10 | ||
| 2024-06-30 | $9.00K 10-Q · filed 2025-11-10 | -$68.00K derived: sum of 2 quarters · filed 2025-11-10 | |||
| 2024-03-31 | -$77.00K 10-Q · filed 2025-11-10 | ||||
| 2023-12-31 | $86.00K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$18.00K 10-Q · filed 2024-11-14 | -$21.00K derived: sum of 2 quarters · filed 2024-11-14 | $26.00K derived: sum of 3 quarters · filed 2024-11-14 | ||
| 2023-06-30 | -$3.00K 10-Q · filed 2024-11-14 | $44.00K derived: sum of 2 quarters · filed 2024-11-14 | |||
| 2023-03-31 | $47.00K 10-Q · filed 2024-11-14 | ||||
| 2022-12-31 | -$47.00K 10-K · filed 2024-03-21 | ||||
| 2022-09-30 | $40.00K 10-Q · filed 2023-11-09 | -$57.00K derived: sum of 2 quarters · filed 2023-11-09 | -$209.00K derived: sum of 3 quarters · filed 2023-11-09 | ||
| 2022-06-30 | -$97.00K 10-Q · filed 2023-11-09 | -$249.00K derived: sum of 2 quarters · filed 2023-11-09 | |||
| 2022-03-31 | -$152.00K 10-Q · filed 2023-11-09 | ||||
| 2021-12-31 | -$6.00K 10-K · filed 2023-03-16 | ||||
| 2021-09-30 | -$1.00K 10-Q · filed 2022-11-10 | -$3.00K derived: sum of 2 quarters · filed 2022-11-10 | -$6.00K derived: sum of 3 quarters · filed 2022-11-10 | ||
| 2021-06-30 | -$2.00K 10-Q · filed 2022-11-10 | -$5.00K derived: sum of 2 quarters · filed 2022-11-10 | |||
| 2021-03-31 | -$3.00K 10-Q · filed 2022-11-10 | ||||
| 2020-12-31 | $6.00K 10-K · filed 2022-03-17 | ||||
| 2020-09-30 | $1.00K 10-Q · filed 2021-11-01 | $12.00K derived: sum of 2 quarters · filed 2021-11-01 | |||
| 2020-06-30 | $11.00K 10-Q · filed 2021-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |